Recent acquisitions have highlighted the evolving relationship of instrument companies and the molecular diagnostics market. Last month, QIAGEN acquired Digene, the largest provider of human papillomavirus (HPV) diagnostics tests, for $1.6 billion (see IBO 6/15/07). Earlier this year, Agilent acquired Stratagene for $246.2 million (see IBO 4/15/07). These developments follow acquisitions last year by Luminex […]
In fiscal 2006, productivity of selected analytical and life science instrument companies increased, but at a slower rate than the previous year, as new employee growth outpaced revenue growth. Following initial productivity gains for larger companies, spurred by IT investments, manufacturing efficiencies and increased outsourcing, such a slowing is not unusual. In addition, as the […]
The 55th American Society for Mass Spectrometry (ASMS) Conference on Mass Spectrometry and Allied Topics took place at the Indiana Convention Center in Indianapolis, Indiana from June 3 to 7. Just a week earlier, Indianapolis was the sight of the famous Indianapolis 500 race, but for MS enthusiasts, this was the week to be in […]
Although the range of new product introductions at this year’s ASMS meeting did not match the scale or scope of last year, there were still a number of significantly new mass spectrometers and related products that will no doubt have a major impact on the mass spectrometry market. The most common theme among these new […]
Founded in 1999, today Fluidigm has over 100 employees and subsidiaries in Europe, Japan and Singapore. Last year, the company introduced its second product platform, the Biomark System for gene expression using quantitative real-time PCR. Based on integrated fluidic circuit technology, the Biomark System enables nanofluidic manipulation and mixing of reagents and samples in a […]
IBO has selected LECO’s new TruTOF HT as the best new product from this year’s ASMS meeting in Indianapolis. Although the aesthetics of this new GC-TOF mass spectrometer are quite subdued, everything else about the new system is to the contrary. For starters, the system is a benchtop design, comparable in size to the only […]
Integrating organizational structures has been the focus of Horiba and Shimadzu, two of the largest analytical instrument companies. Based in Japan, both companies have sought in recent years to improve profitability through consolidating operations, new manufacturing facilities and strengthening their US businesses. As the results for each company’s most recent fiscal years show, these efforts […]
This issue, IBO has made a of couple changes to its Life Science Sales Index. Gene Logic, Tripos and Molecular Devices were removed from the Index. Tripos sold its Discovery Informatics division in March (see IBO 11/30/06), while Gene Logic increased the service orientation of its business. Molecular Devices was acquired by MDS on March […]
Many people worldwide depend on drugs that have gone off-patent. According to analyses by the FDA, prices of generic drugs can be as low as 20% of the cost of a brand-name drug, and these significant price drops often occur when two or three generic versions of a drug come onto the market. In 2004, […]
The recent news of the presence of the industrial chemical melamine in US pet food and diethylene glycol in Central American toothpaste has heightened concern over the chemical contamination of imported products. Chinese toothpaste has been linked to the deaths of 51 people in Panama last year. Pet food made with melamine, contained in mislabeled […]
Pay Invoice
Latest Blogs
-
Lab Instrument Sales in China Collapse
March 29, 2024 1:15 pm
-
Pittcon 2024 Comes to San Diego
February 14, 2024 1:10 pm
Sitemap
Your Data and Privacy
About Us
IBO (Instrument Business Outlook) is a twice-monthly newsletter aimed at providing decision-makers with the latest and most complete information available on the life science and analytical instrument industry, and lab product markets. IBO delivers the latest curated industry news, information and trends, as well as SDi data and analysis to deliver the maximum in industry insight with a minimum time investment for executives and investors.
